title: Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
abstract: OBJECTIVE
  To investigate changes in oxidative stress in Crohn's disease (CD) before and after anti-tumor necrosis factor (TNF)-α treatment.
  
  
  METHODS
  A total of 42 patients with active CD, who were scheduled to be treated by anti-TNF-α antibodies, were enrolled. Serum levels of diacron-reactive oxygen metabolites (d-ROM), biological antioxidant potential (BAP), and modified ratio of oxidative stress and antioxidant capacity (m-OA) were measured using the Free Radical Analytical System before and 8 wk after induction of therapy with infliximab or adalimumab. The values for oxidative stress were correlated with disease activity and clinical response as determined by the CD activity index (CDAI) at 8 and 54 wk after the therapy.
  
  
  RESULTS
  Prior to treatment, d-ROM showed significant correlations with CDAI (r = 0.42, P < 0.01). There was a significant negative correlation between m-OA and CDAI before and after treatment (r = -0.48 vs r = -0.42, P < 0.01). CDAI and d-ROM had decreased significantly by 8 wk after treatment (CDAI; 223.3 ± 113.2 vs 158.3 ± 73.4, P < 0.01, d-ROM; 373 ± 133 vs 312 ± 101, P < 0.05). However, neither BAP nor m-OA had changed significantly. In patients who had responded to the treatment at 8 wk, d-ROM, BAP, and m-OA levels before treatment did not differ significantly between patients with and without loss of response.
  
  
  CONCLUSIONS
  Anti-TNF-α therapy decreases oxidative stress in patients with CD, but does not alter the production of antioxidants. Dysregulation of antioxidants may be associated with the disease.
authors.affiliation: Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka City, Iwate 020-8505, Japan.
authors.forename: Kazunari
authors.initials: K
authors.lastname: Yamamoto
authors.affiliation: Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka City, Iwate 020-8505, Japan.
authors.forename: Toshimi
authors.initials: T
authors.lastname: Chiba
authors.affiliation: Kazunari Yamamoto, Toshimi Chiba, Takayuki Matsumoto, Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka City, Iwate 020-8505, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsumoto
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D003424:Crohn Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D010865:Pilot Projects; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab
keywords: Anti-tumor necrosis factor-α antibody; Crohn’s disease; Oxidative stress; Severity